Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

Presentation VIVA 2018

LUTONIX BTK Trial

Presenter: Jihad Mustapha

November 09, 2018

Presentation VIVA 2018

TOBA II 12-Month Data

Presenter: William Gray

November 09, 2018

Presentation VIVA 2018

1-Year Outcomes for Eluvia in Long Lesions

Presenter: William A. Gray

November 09, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

Presentation VIVA 2017

Results from the IN.PACT SFA Randomized Trial

Presenter: Peter A. Schneider

September 15, 2017

Presentation VIVA 2017

ILLUMENATE European Randomized Trial: 2-Year Results

Presenter: Marianne Brodmann

September 11, 2017

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

L.A. McKeown

October 12, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

L.A. McKeown

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

L.A. McKeown

September 20, 2016

Advertisement

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

LUTONIX BTK Trial

TOBA II 12-Month Data

1-Year Outcomes for Eluvia in Long Lesions

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Results from the IN.PACT SFA Randomized Trial

ILLUMENATE European Randomized Trial: 2-Year Results

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content